Gelteq Announces New Product Development Agreement with Melbourne Health for Novel Bowel Polyp Growth Reduction Compound
Gelteq (ASX:GELS) entered a Product Development and Profit Share Agreement with Melbourne Health on October 9, 2025 to develop oral products containing HAMSB (high-amylose maize starch butyrylated), a compound linked in an Australian study to reduced bowel polyp initiation. The partners will use Gelteq's proprietary gel-based oral delivery platform and Gelteq's Clayton, Victoria facility will handle manufacturing, marketing, and commercialisation. The agreement includes a profit-sharing model granting Melbourne Health a share of net profits from future product sales. The program aims to create a ready-to-consume HAMSB product targeting preventive colorectal health and improved patient compliance.
Gelteq (ASX:GELS) ha stipulato un Accordo di Sviluppo di Prodotto e di Condivisione dei Profitti con Melbourne Health il 9 ottobre 2025 per sviluppare prodotti orali contenenti HAMSB (amido di mais ad alto contenuto di amilosio butirrato), una sostanza collegata in uno studio australiano alla riduzione dell'insorgenza dei polipi intestinali. I partner utilizzeranno la piattaforma proprietaria di Gelteq per la somministrazione orale basata su gel e lo stabilimento di Gelteq a Clayton, Victoria, gestirà la produzione, il marketing e la commercializzazione. L'accordo comprende un modello di condivisione dei profitti che concede a Melbourne Health una quota dei profitti netti provenienti dalle future vendite del prodotto. Il programma punta a creare un prodotto HAMSB pronto al consumo mirato alla salute preventiva del colon e a una migliore adesione del paziente.
Gelteq (ASX:GELS) firmó un Acordo de Desarrollo de Producto y Participación en las Ganancias con Melbourne Health el 9 de octubre de 2025 para desarrollar productos orales que contengan HAMSB (almidón de maíz de alto contenido en amilosas butirriladas), una sustancia vinculada en un estudio australiano a una reducción en la iniciación de pólipos intestinales. Los socios utilizarán la plataforma propietaria de Gelteq para la entrega oral basada en gel y la instalación de Gelteq en Clayton, Victoria, se encargará de la fabricación, marketing y comercialización. El acuerdo incluye un modelo de participación en las ganancias que otorga a Melbourne Health una porción de las ganancias netas de las ventas futuras del producto. El programa apunta a crear un producto HAMSB listo para consumir, dirigido a la salud preventiva del colon y a una mejor adherencia del paciente.
Gelteq (ASX:GELS)는 2025년 10월 9일 멜버른 헬스와 HAMSB를 포함하는 경구 제제 개발 및 이익 공유 계약을 체결했습니다. HAMSB는 고아밀로스 옥수수 전분 부티릴화물이며, 호주 연구에서 대장의 폴립 발생 억제와 연관이 있는 물질로 알려져 있습니다. 파트너들은 Gelteq의 젤 기반 경구 전달 플랫폼을 이용하고 Clayton, Victoria에 위치한 Gelteq 시설이 제조, 마케팅 및 상용화를 담당합니다. 이 계약은 향후 제품 판매의 순이익 일부를 Melbourne Health가 받는 이익 공유 모델을 포함합니다. 이 프로그램은 예방적 대장 건강을 목표로 하고 환자의 순응도를 높이는 HAMSB 즉시 섭취 가능 제품을 개발하는 것을 목표로 합니다.
Gelteq (ASX:GELS) a conclu un Accord de Développement de Produit et de Partage des Profits avec Melbourne Health le 9 octobre 2025 pour développer des produits oraux contenant HAMSB (amidon de maïs à haute teneur en amylose butirylé), une substance associée dans une étude australienne à une réduction de l'initiation des polypes colorectaux. Les partenaires utiliseront la plateforme propriétaire de Gelteq pour l'administration orale sous forme de gel et l'installation de Gelteq à Clayton, Victoria, gérera la fabrication, le marketing et la commercialisation. L'accord comprend un modèle de partage des profits accordant à Melbourne Health une part des bénéfices nets des ventes futures du produit. Le programme vise à créer un produit HAMSB prêt à être consommé, ciblant la prévention des problèmes colorectaux et une meilleure adhérence des patients.
Gelteq (ASX:GELS) hat am 9. Oktober 2025 mit Melbourne Health eine Produktentwicklungs- und Gewinnbeteiligungsvereinbarung geschlossen, um orale Produkte mit HAMSB (hochamylose Maisstärke Butyryliert) zu entwickeln, eine Verbindung, die in einer australischen Studie mit einer reduzierten Entstehung von Darmpolypen in Verbindung gebracht wird. Die Partner werden Gelteqs proprietäre gelbasierte orale Abgabesystemplattform verwenden und Gelteqs Standort in Clayton, Victoria, wird Herstellung, Marketing und Kommerzialisierung übernehmen. Die Vereinbarung umfasst ein Gewinnausschüttungsmodell, das Melbourne Health einen Anteil am Nettogewinn zukünftiger Produktverkäufe gewährt. Das Programm zielt darauf ab, ein sofort einnehmbares HAMSB-Produkt zu schaffen, das auf vorbeugende Darmgesundheit abzielt und die Patientencompliance verbessert.
Gelteq (ASX:GELS) أبرمت اتفاقية تطوير منتج ومشاركة الأرباح مع Melbourne Health في 9 أكتوبر 2025 لتطوير منتجات فموية تحتوي على HAMSB (نشا الذرة عالي التماثل ولكنيران)؛ وهو مركب ربطته دراسة أسترالية بتقليل بدء تكوّن الزوائد المعوية. سيستخدم الشركاء منصة Gelteq الحاصلة على براءة اختراع لتوصيل فموي يعتمد على الهلام، وسيتولى منشأة Gelteq في Clayton، فيكتوريا التصنيع والتسويق والتجاري، كما تتضمن الاتفاقية نموذج مشاركة الأرباح الذي يمنح Melbourne Health جزءاً من صافي الأرباح من مبيعات المنتج في المستقبل. يهدف البرنامج إلى إنشاء منتج HAMSB جاهز للاستخدام يستهدف الصحة الوقائية للقولون وتحسين امتثال المرضى.
Gelteq (ASX:GELS) 于 2025 年 10 月 9 日与 Melbourne Health 签订 产品开发与利润分享协议，以开发含有 HAMSB（高直链淀粉玉米淀粉丁酯化）的口服产品，该化合物在一项澳大利亚研究中与降低肠道息肉发生有关。双方将使用 Gelteq 的专有凝胶基口服给药平台，Gel teq 在克莱顿（维多利亚州）的设施将负责制造、市场营销与商业化。协议包含一个利润分享模型，向 Melbourne Health 授予未来产品销售净利润的一部分。该计划旨在打造可直接食用的 HAMSB 产品，面向预防性结直肠健康及提升患者依从性。
- Signed Product Development and Profit Share Agreement with Melbourne Health
- Leverages Gelteq proprietary gel-based oral delivery platform
- Gel-based manufacturing, marketing, and commercialisation assigned to Gelteq facility in Clayton
- Profit-sharing model grants Melbourne Health share of net profits from commercialization
- No financial terms or revenue projections disclosed
- Clinical evidence cited is from prior study; commercial efficacy and approvals not confirmed
- Commercial success depends on future development, regulatory clearance, and market uptake
Insights
Gelteq partners with Melbourne Health to develop a HAMSB gel product; commercial profit-share and clinical evidence underpin the collaboration.
Gelteq will use its proprietary gel oral-delivery platform to formulate a ready-to-consume product containing HAMSB, an acylated high-amylose maize starch that Melbourne Health and CSIRO have researched for reducing bowel polyp growth. The arrangement explicitly assigns Gelteq responsibility for manufacturing, marketing and commercialisation at its Clayton, Victoria facility, while Melbourne Health receives a share of net profits under the Agreement.
Key dependencies and risks include confirmation of clinical benefit beyond the cited study (presented at Digestive Disease Week
MELBOURNE, Australia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has entered into a Product Development and Profit Share Agreement (the “Agreement”), with Melbourne Health (“Melbourne Health”), operator of The Royal Melbourne Hospital and one of Australia’s top public health services with extensive research capabilities.
Under the Agreement, Gelteq and Melbourne Health will develop new products incorporating high-amylose maize starch butyrylated, or HAMSB, a unique compound with the potential to reduce bowel polyp growth which could lower the risk of bowel cancer.
HAMSB, a form of acylated starch, has been the focus of significant research conducted by the Melbourne Health and the Commonwealth Scientific and Industrial Research Organisation (“CSIRO”). A recent study has demonstrated HAMSB’s significant effects on polyp initiation pointing towards an alternative and innovative approach in colorectal health management. The results of this Australian study, originally presented as part of Digestive Disease Week 2024, are accessible online here.
Melbourne Health and Gelteq will leverage Gelteq’s proprietary gel-based oral delivery platform to develop and formulate a ready-to-consume HAMSB product designed to enhance patient compliance and efficacy in preventive health applications.
“This collaboration with Melbourne Health marks a pivotal step in translating cutting-edge clinical research into a potentially commercially viable product that could meaningfully reduce the risk of bowel cancer,” said Nathan Givoni, CEO of Gelteq. “By combining Melbourne Health’s expertise and robust research foundation with Gelteq’s innovative gel technology, we seek to deliver meaningful health benefits in a convenient, user-friendly format.”
Many bowel cancers originate from polyps, which underscores the need for new approaches to bowel polyp prevention and reduction in addition to good colorectal health management and regular screenings. Although bowel cancers remains highly treatable when detected early, bowel cancer is the fourth most common cancer diagnosis in Australia, affecting up to 1 in 20 people by age 85, according to Cancer Council, Australia’s leading cancer charity,. In the United States, the Colorectal Cancer Alliance identifies colorectal cancers as the second leading cause of cancer deaths in the United States.
Under the Agreement, Gelteq and Melbourne Health have established a profit-sharing model that will provide Melbourne Health with a share of net profits from future product commercialisation. The profit-sharing model recognizes Melbourne Health’s pivotal role in contributing to research and fostering collaborative innovation in healthcare.
Gelteq’s research facility in Clayton, Victoria, where the Company is responsible for all manufacturing, marketing, and commercialisation activities, will conduct the product development program.
About Gelteq Ltd.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit www.gelteq.com.
Gelteq Contact:
Investor Relations
Matt Kreps, Darrow Associates IR
+1-214-597-8200
mkreps@darrowir.com
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 20-F filed on November 15, 2024 and its Registration Statement on Form F-1 initially filed with the SEC on July 1, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
FAQ
What did Gelteq announce on October 9, 2025 regarding HAMSB and GELS stock?
How will the Gelteq and Melbourne Health profit share work for GELS product sales?
Where will Gelteq manufacture and commercialise the HAMSB product for GELS?
Does the announcement confirm HAMSB prevents bowel cancer for GELS investors?
What role did Melbourne Health and CSIRO play in the HAMSB research mentioned for GELS?
How might the GELS agreement affect Gelteq's product pipeline timeline?
